Evicenter
P&T meetings

SL1009 (sodium dichloroacetate)

Pyruvate dehydrogenase complex deficiency

Manufacturer
Saol Therapeutics
Regulatory submission
NDA resubmitted June 2026
Launch
Not announced
Last updated
78 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

6 evidence topics · 5 sources

Absorption and distribution

“An oral dose of DCA is rapidly absorbed and widely distributed within minutes of administration.” (opens the source at this quote in a new tab)

Central nervous system distribution

“It readily crosses the blood-brain barrier and can be measured in cerebrospinal fluid.” (opens the source at this quote in a new tab)

Metabolism and inhibition of clearance

“DCA inhibits GSTZ1/MAAI, leading to delayed plasma drug clearance and to accumulation of potentially toxic tyrosine intermediates.” (opens the source at this quote in a new tab)

Repeated dosing and phenoconversion

“DCA-induced inactivation of GSTZ1 resulted in phenoconversion of all subjects into slow metabolizers after repeated dosing.” (opens the source at this quote in a new tab)

Chronic dosing and accumulation

“Chronic administration of DCA leads to inhibition of DCA metabolism and potential accumulation to levels that result in side effects.” (opens the source at this quote in a new tab)

Metabolic autoinhibition

“DCA inhibits GSTz1/MAAI, which leads to a marked decrease in its plasma clearance.” (opens the source at this quote in a new tab)